Pramipexole-induced somnolence and episodes of daytime sleep

Hauser, Robert A.; Gauger, Lisa; Anderson, William; Zesiewicz, Theresa A.

doi:10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n

Cited by 160 publications

(86 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in our study, a significant correlation was not identified between levodopa dosage and EDS (Table 2), and two other studies also reported no such correlation (Gjerstad, Alves, Wentzel‐Larsen, Aarsland, & Larsen, 2006; Kumar, Bhatia, & Behari, 2003). DAs therapy contributes to EDS and sudden somnolence (Hauser, Gauger, Anderson, & Zesiewicz, 2000; Pal, Bhattacharya, Agapito, & Chaudhuri, 2001). Our results confirmed that EDS could be augmented by more DA use and higher DA dosage (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Sleep disturbances in Taiwanese patients with Parkinson's disease

Lin

Chen

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

IntroductionSleep disturbance is a common nonmotor symptom of Parkinson's disease (PD) and strongly affects patients’ quality of life. The relationship between excessive daytime sleepiness (EDS) and nighttime problems remains uncertain. Arguments persist regarding the risk factors for sleep disturbance among patients with PD. Furthermore, the prevalence of EDS appears to be lower in Asian countries. Herein, we conducted the study to describe the characteristics of sleep problems in a sample of Taiwanese PD patients and delineate the difference with reported sleep disturbances in Caucasian PD patients from the literature.MethodsPatients with PD were recruited from the outpatient clinic of a tertiary medical center and were evaluated using standardized assessment protocols, including the Parkinson's Disease Sleep Scale (PDSS), the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and 39‐Item Parkinson's Disease Questionnaire (PDQ‐39).ResultsA total of 225 patients with PD were recruited. The mean age of patients with PD was 65.7 years old and the mean disease duration was 8.18 years. Among the patients, 53.8% were defined as poor sleepers (PSQI > 5) and 26.3% had EDS. Seventy‐one percent of the poor sleepers used hypnotic medications. The poor sleepers were worse in the scores of Unified Parkinson's Disease Rating Scale (UPDRS), PDSS, and the PDQ‐39, and received higher levodopa daily dosage. A PDSS score of <126 indicate that a patient with PD was a poor sleeper. EDS was positively correlated with advanced Hoehn and Yahr stages and use of dopamine agonists but not with levodopa daily dosage and levodopa equivalent daily dosage.ConclusionsTaiwanese patients with PD had a lower prevalence of EDS compared with the literatures reported in Caucasian patients. We identify and suggest that PDSS total score, rather than subcategory items, should be used to predict poor sleep among patients with PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Sleep disturbances in Taiwanese patients with Parkinson's disease

Lin

Chen

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…71,72 These reports engendered an unusual amount of interest, response, and controversy. 72,73 Based on the report by Frucht et al, 70 the FDA and health organizations around the world required amendments to package inserts, including a black box warning in the United States with a statement that patients should not drive until "they have gained sufficient experience with [pramipexole] to gauge whether or not it affects their mental and/or motor performance adversely. "…”

Section: Phase III Clinical Trial Results In Advanced Patientsmentioning

confidence: 99%

Current Status of Symptomatic Medical Therapy in Parkinson’s Disease

Factor

2008

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Symptomatic medical therapies for Parkinson's disease (PD) have been disease modifying and have led to improvement in daily function, quality of life, and survival. For 40 years, these therapies have been primarily dopaminergic, and currently include the dopamine (DA) precursor levodopa (LD), DA agonists, catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors. The roles of all these classes of agents have evolved, with significant changes occurring since the early 2000s. This article reviews the current literature for each of these classes of drugs, with a focus on efficacy and place in the therapeutic scheme. Levodopa is no longer considered to be toxic and, thus, its early use is not only appropriate but recommended.Ergot agonists are no longer in use, and new agents administered in patch form or subcutaneous injections have been approved. The COMT inhibitor tolcapone, with its significant efficacy, has been reintroduced, and two new MAO inhibitors have been approved. Selected safety issues are discussed, including the incidence of melanoma in relation to LD; pathological gambling and DA agonists; hepatic toxicity of tolcapone; and the tyramine or so-called cheese reaction with MAO B inhibitors. The article closes with a discussion of future directions and new drugs under development.

show abstract

“…Previous studies have suggested that an impairment in working memory underpins the decline in episodic memory in PD [74,75]. It should follow, therefore, that drugs which enhance working memory [53,58,71] should also exert (secondary) benefits on recollection. Accordingly, if pramipexole improves working memory in PD, and recollection deficits in PD are contingent, at least in part, on working memory deficits, then our D2 agonist group should show improved recollection ON compared to OFF medicationwhich is in fact the opposite to that observed.…”

Section: Discussionmentioning

confidence: 97%

“…It could be argued that the negative impact of D2 agonists on recollection is secondary to the sometime reported side-effects of somnolence and reduced vigilance of pramipexole and ropinirole [71,72]. However, this parsimonious explanation fails to stand up to scrutiny, since previous work has shown that D2 agonists, and pramipexole in particular, enhances rather than impairs working memory [53,58,73], and probabilistic reversal learning [53].…”

Section: Discussionmentioning

confidence: 99%